Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network

Aurelius Omlin, Maurizio Amichetti, David Azria, Bernard F. Cole, Philippe Fourneret, Philip Poortmans, Diana Naehrig, Robert C. Miller, Marco Krengli, Cristina Gutierrez Miguelez, David Morgan, Hadassah Goldberg, Luciano Scandolaro, Pauline Gastelblum, Mahmut Ozsahin, Dagmar Dohr, David Christie, Ulrich Oppitz, Ufuk Abacioglu, Guenther Gruber

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Background: Outcome data in young women with ductal carcinoma in situ (DCIS) are rare. The benefits of boost radiotherapy in this group are also unknown. We aimed to assess the effect of boost radiotherapy in young patients with DCIS. Methods: We included 373 women from 18 institutions who met the following inclusion criteria: having tumour status Tis and nodal status (N)0, age 45 years or younger at diagnosis, and having had breast-conserving surgery. 57 (15%) patients had no radiotherapy after surgery, 166 (45%) had radiotherapy without boost (median dose 50 Gy [range 40-60]), and 150 (40%) had radiotherapy with boost (60 Gy [53-76]). The primary outcome was local relapse-free survival. Findings: Median follow-up was 72 months (range 1-281). 55 (15%) patients had local relapse. Local relapse-free survival at 10 years was 46% (95% CI 24-67) for patients given no radiotherapy, 72% (61-83) for those given radiotherapy without boost, and 86% (78-93) for those given radiotherapy and boost (difference between all three groups, p<0·0001). Age, margin status, and radiotherapy dose were significant predictors of local relapse-free survival. Compared with patients who had no radiotherapy, those who had radiotherapy had a decreased risk of local relapse (without boost, hazard ratio 0·33 [95% CI 0·16-0·71], p=0·004; with boost, 0·15 [0·06-0·36], p<0·0001). Interpretation: In the absence of randomised trials, boost radiotherapy should be considered in addition to surgery for breast-conserving treatment for DCIS.

Original languageEnglish (US)
Pages (from-to)652-656
Number of pages5
JournalLancet Oncology
Volume7
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Multicenter Studies
Radiotherapy
Retrospective Studies
Neoplasms
Recurrence
Segmental Mastectomy
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Boost radiotherapy in young women with ductal carcinoma in situ : a multicentre, retrospective study of the Rare Cancer Network. / Omlin, Aurelius; Amichetti, Maurizio; Azria, David; Cole, Bernard F.; Fourneret, Philippe; Poortmans, Philip; Naehrig, Diana; Miller, Robert C.; Krengli, Marco; Gutierrez Miguelez, Cristina; Morgan, David; Goldberg, Hadassah; Scandolaro, Luciano; Gastelblum, Pauline; Ozsahin, Mahmut; Dohr, Dagmar; Christie, David; Oppitz, Ulrich; Abacioglu, Ufuk; Gruber, Guenther.

In: Lancet Oncology, Vol. 7, No. 8, 08.2006, p. 652-656.

Research output: Contribution to journalArticle

Omlin, A, Amichetti, M, Azria, D, Cole, BF, Fourneret, P, Poortmans, P, Naehrig, D, Miller, RC, Krengli, M, Gutierrez Miguelez, C, Morgan, D, Goldberg, H, Scandolaro, L, Gastelblum, P, Ozsahin, M, Dohr, D, Christie, D, Oppitz, U, Abacioglu, U & Gruber, G 2006, 'Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network', Lancet Oncology, vol. 7, no. 8, pp. 652-656. https://doi.org/10.1016/S1470-2045(06)70765-3
Omlin, Aurelius ; Amichetti, Maurizio ; Azria, David ; Cole, Bernard F. ; Fourneret, Philippe ; Poortmans, Philip ; Naehrig, Diana ; Miller, Robert C. ; Krengli, Marco ; Gutierrez Miguelez, Cristina ; Morgan, David ; Goldberg, Hadassah ; Scandolaro, Luciano ; Gastelblum, Pauline ; Ozsahin, Mahmut ; Dohr, Dagmar ; Christie, David ; Oppitz, Ulrich ; Abacioglu, Ufuk ; Gruber, Guenther. / Boost radiotherapy in young women with ductal carcinoma in situ : a multicentre, retrospective study of the Rare Cancer Network. In: Lancet Oncology. 2006 ; Vol. 7, No. 8. pp. 652-656.
@article{877114fc035b4a06ba3c245bf73c5a2b,
title = "Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network",
abstract = "Background: Outcome data in young women with ductal carcinoma in situ (DCIS) are rare. The benefits of boost radiotherapy in this group are also unknown. We aimed to assess the effect of boost radiotherapy in young patients with DCIS. Methods: We included 373 women from 18 institutions who met the following inclusion criteria: having tumour status Tis and nodal status (N)0, age 45 years or younger at diagnosis, and having had breast-conserving surgery. 57 (15{\%}) patients had no radiotherapy after surgery, 166 (45{\%}) had radiotherapy without boost (median dose 50 Gy [range 40-60]), and 150 (40{\%}) had radiotherapy with boost (60 Gy [53-76]). The primary outcome was local relapse-free survival. Findings: Median follow-up was 72 months (range 1-281). 55 (15{\%}) patients had local relapse. Local relapse-free survival at 10 years was 46{\%} (95{\%} CI 24-67) for patients given no radiotherapy, 72{\%} (61-83) for those given radiotherapy without boost, and 86{\%} (78-93) for those given radiotherapy and boost (difference between all three groups, p<0·0001). Age, margin status, and radiotherapy dose were significant predictors of local relapse-free survival. Compared with patients who had no radiotherapy, those who had radiotherapy had a decreased risk of local relapse (without boost, hazard ratio 0·33 [95{\%} CI 0·16-0·71], p=0·004; with boost, 0·15 [0·06-0·36], p<0·0001). Interpretation: In the absence of randomised trials, boost radiotherapy should be considered in addition to surgery for breast-conserving treatment for DCIS.",
author = "Aurelius Omlin and Maurizio Amichetti and David Azria and Cole, {Bernard F.} and Philippe Fourneret and Philip Poortmans and Diana Naehrig and Miller, {Robert C.} and Marco Krengli and {Gutierrez Miguelez}, Cristina and David Morgan and Hadassah Goldberg and Luciano Scandolaro and Pauline Gastelblum and Mahmut Ozsahin and Dagmar Dohr and David Christie and Ulrich Oppitz and Ufuk Abacioglu and Guenther Gruber",
year = "2006",
month = "8",
doi = "10.1016/S1470-2045(06)70765-3",
language = "English (US)",
volume = "7",
pages = "652--656",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "8",

}

TY - JOUR

T1 - Boost radiotherapy in young women with ductal carcinoma in situ

T2 - a multicentre, retrospective study of the Rare Cancer Network

AU - Omlin, Aurelius

AU - Amichetti, Maurizio

AU - Azria, David

AU - Cole, Bernard F.

AU - Fourneret, Philippe

AU - Poortmans, Philip

AU - Naehrig, Diana

AU - Miller, Robert C.

AU - Krengli, Marco

AU - Gutierrez Miguelez, Cristina

AU - Morgan, David

AU - Goldberg, Hadassah

AU - Scandolaro, Luciano

AU - Gastelblum, Pauline

AU - Ozsahin, Mahmut

AU - Dohr, Dagmar

AU - Christie, David

AU - Oppitz, Ulrich

AU - Abacioglu, Ufuk

AU - Gruber, Guenther

PY - 2006/8

Y1 - 2006/8

N2 - Background: Outcome data in young women with ductal carcinoma in situ (DCIS) are rare. The benefits of boost radiotherapy in this group are also unknown. We aimed to assess the effect of boost radiotherapy in young patients with DCIS. Methods: We included 373 women from 18 institutions who met the following inclusion criteria: having tumour status Tis and nodal status (N)0, age 45 years or younger at diagnosis, and having had breast-conserving surgery. 57 (15%) patients had no radiotherapy after surgery, 166 (45%) had radiotherapy without boost (median dose 50 Gy [range 40-60]), and 150 (40%) had radiotherapy with boost (60 Gy [53-76]). The primary outcome was local relapse-free survival. Findings: Median follow-up was 72 months (range 1-281). 55 (15%) patients had local relapse. Local relapse-free survival at 10 years was 46% (95% CI 24-67) for patients given no radiotherapy, 72% (61-83) for those given radiotherapy without boost, and 86% (78-93) for those given radiotherapy and boost (difference between all three groups, p<0·0001). Age, margin status, and radiotherapy dose were significant predictors of local relapse-free survival. Compared with patients who had no radiotherapy, those who had radiotherapy had a decreased risk of local relapse (without boost, hazard ratio 0·33 [95% CI 0·16-0·71], p=0·004; with boost, 0·15 [0·06-0·36], p<0·0001). Interpretation: In the absence of randomised trials, boost radiotherapy should be considered in addition to surgery for breast-conserving treatment for DCIS.

AB - Background: Outcome data in young women with ductal carcinoma in situ (DCIS) are rare. The benefits of boost radiotherapy in this group are also unknown. We aimed to assess the effect of boost radiotherapy in young patients with DCIS. Methods: We included 373 women from 18 institutions who met the following inclusion criteria: having tumour status Tis and nodal status (N)0, age 45 years or younger at diagnosis, and having had breast-conserving surgery. 57 (15%) patients had no radiotherapy after surgery, 166 (45%) had radiotherapy without boost (median dose 50 Gy [range 40-60]), and 150 (40%) had radiotherapy with boost (60 Gy [53-76]). The primary outcome was local relapse-free survival. Findings: Median follow-up was 72 months (range 1-281). 55 (15%) patients had local relapse. Local relapse-free survival at 10 years was 46% (95% CI 24-67) for patients given no radiotherapy, 72% (61-83) for those given radiotherapy without boost, and 86% (78-93) for those given radiotherapy and boost (difference between all three groups, p<0·0001). Age, margin status, and radiotherapy dose were significant predictors of local relapse-free survival. Compared with patients who had no radiotherapy, those who had radiotherapy had a decreased risk of local relapse (without boost, hazard ratio 0·33 [95% CI 0·16-0·71], p=0·004; with boost, 0·15 [0·06-0·36], p<0·0001). Interpretation: In the absence of randomised trials, boost radiotherapy should be considered in addition to surgery for breast-conserving treatment for DCIS.

UR - http://www.scopus.com/inward/record.url?scp=33746447014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746447014&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(06)70765-3

DO - 10.1016/S1470-2045(06)70765-3

M3 - Article

C2 - 16887482

AN - SCOPUS:33746447014

VL - 7

SP - 652

EP - 656

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 8

ER -